Drug Profile
Folitixorin - ADVENTRX
Alternative Names: 5-10 Methylenetetrahydrofolate; 5-FU biomodulator - ADVENTRX; ANX-510; CoFactor; Methylenetetrahydrofolic acidLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Sahlgrenska University Hospital; University of Southern California
- Developer ADVENTRX Pharmaceuticals
- Class 3-ring heterocyclic compounds; Antineoplastics; Chemoprotectants; Chemosensitisers; Folic acids; Imidazolidines; Pyrimidinones; Small molecules; Tetrahydrofolates
- Mechanism of Action Antimetabolites; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Pancreatic cancer
Most Recent Events
- 23 Oct 2008 Discontinued - Phase-II for Breast cancer in Argentina (IV)
- 23 Oct 2008 Discontinued - Phase-II for Breast cancer in Mexico (IV)
- 23 Oct 2008 Discontinued - Phase-II for Breast cancer in Peru (IV)